AGM
EPZM

Alpine Global Management’s Epizyme, Inc EPZM Stock Holding History

Alpine Global Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-75,000
Closed -$86 – 697
2022
Q1 		$86 Buy
75,000
+25,608
+52% +$41.7K 0.02% 291
2021
Q4 		$123K Buy
+49,392
New +$194K 0.02% 614

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alpine Global Management's EPZM Position: Q2 2022 in Review

Alpine Global Management sold out of Epizyme, Inc (EPZM) in Q2 2022, closing a stake of 75,000 shares — an estimated $86 sold.

Alpine Global Management first reported a position in EPZM in Q4 2021 and held it in 2 quarters. The position peaked at $123K in Q4 2021. 93 funds tracked by Wall St. Rank hold EPZM as of Q2 2022.

  • Alpine Global Management reported no remaining Epizyme, Inc position as of Q2 2022 after selling out during the quarter.
  • Alpine Global Management sold 75,000 Epizyme, Inc shares in Q2 2022, an estimated $86.
  • Alpine Global Management first reported a position in Epizyme, Inc in Q4 2021 and held it in 2 quarters.
  • Alpine Global Management's Epizyme, Inc position peaked at $123K in Q4 2021.
  • 93 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2022.

Based on Alpine Global Management's 13F filing for Q2 2022, filed 15 Aug 2022.